ICE/ENDO 2014, Chicago, United States Of America, 21 - 24 April 2014, pp.506
Dehydroepiandrosterone (DHEA) and its sulfated metabolite, dehydroepiandrosterone sulfate (DHEAS), has previously been reported to decrease hyperglycemia, obesity, cancer, and autoantibody generation in a number of animal models. DHEAS has been shown to exert potent effects on both humoral and cellular immune response. However, their physiological role in the immune system is unkonown. DHEAS could have immunmodulatory effects. Chronic lymphocytic thyroidtis is a disease that has a immunological pathogenetic basis.
We included 93 premenopousal women for this cross-sectional study. Forty-six patients who were seropositive for thyroglobulin autoantibodies (AntiTg) and/or thyroperoxidase autoantibodies (AntiTPO) were taken as study group. Forty-seven patients who were age metched and seronegative for Antitg and AntiTPO autoantibodies were accepted as control group. All patients were euthyroid. In both group, none of the cases were taking estrogen/progesterone medication and had no polycystic ovary syndrome and hirsutism. All cases enrolled into study had regular menstruation periods and no problem of adrenal insufficiency.
Mean age of antibody positive (+) group was 37 years of old and 33 years fort he control group (p=0,056). No statistical difference in DHEAS serum concentration was found between antibody positive chronic lymphocytic thyroiditis patients and antibody negative control group (mean DHEAS 178 µg/dL versus 172µg/dL, respectively, p=0,76). There was no correlation between DHEAS levels and thyroid autoantibodies.
In the present study, we did not observe any significant differences in serum concentration of DHEAS between study and control group. DHEAS may have immunomodulatory effect. There is limited study in the literature related to DHEAS and autoimmune thyroiditis occurence. In this perspective, further studies are needed.